Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tonix Pharma ( (TNXP) ) just unveiled an announcement.
On November 21, 2025, Tonix Pharmaceuticals amended its Sales Agreement with A.G.P./Alliance Global Partners to increase the maximum aggregate offering price of shares from $150 million to $400 million. This amendment allows Tonix to potentially raise more capital, which could enhance its operational capabilities and strengthen its market position.
The most recent analyst rating on (TNXP) stock is a Sell with a $17.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Underperform.
Tonix Pharma’s overall stock score is primarily impacted by its financial performance and valuation challenges. The company faces significant profitability and cash flow issues, which are reflected in its negative P/E ratio. Technical analysis indicates a bearish trend, with the stock trading below key moving averages and approaching oversold conditions. These factors collectively contribute to a low overall stock score.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative pharmaceutical products.
Average Trading Volume: 974,972
Technical Sentiment Signal: Strong Sell
Current Market Cap: $196.9M
For detailed information about TNXP stock, go to TipRanks’ Stock Analysis page.